

Lunit receives CE mark for breast cancer solution

16 June 2020 | News

Developed by medical AI company Lunit, software detects breast cancer with 97% accuracy

South Korean company Lunit has announced that its Al solution for breast cancer, Lunit INSIGHT MMG, has been CE certified, making it now commercially available across the European Economic Area.

The certified software, Lunit INSIGHT MMG, publicly introduced during the 2018 Radiological Society ofNorth America (RSNA) annual meeting, analyzes mammography images with 97% accuracy, providing the location of lesions suspicious for breast cancer, and an abnormality score that reflects the probability of the existence of detected lesions.

Recently in February, a study using Lunit INSIGHT MMG was published in Lancet Digital Health, showing the added value of Al-aided breast cancer detection from mammography images. The study included a dataset of over 36,000 biopsy-proven, independent cancer positive cases—the largest scale of cancer data among mammography-related Al studies.

The study showed a significant improvement in the performance of radiologists, before and after using AI. According to the study, the AI alone showed 88.8% sensitivity in breast cancer detection, whereas radiologists alone showed 75.3%. When radiologists were aided by AI, the accuracy increased by 9.5% to 84.8%.